Pediatrix Q2 FY26 EPS rises 6.52% to $0.49; net revenue increases 4% to $488 million
MD•Outlook reaffirmed
CEO Mark S. Ordan cited favorable acquisition trends and reimbursement metrics; full-year adjusted EBITDA outlook was reaffirmed at $280 million-$300 million.
Volume trends and reimbursement factors
Same-unit reimbursement-related factors rose 4%, while same-unit patient volume fell 2.1% with NICU days down 3.2%.
Adjusted EBITDA and adjusted EPS increase
Adjusted EBITDA increased to $76 million; adjusted EPS climbed to $0.63 from $0.53.
Pediatrix reports higher quarterly earnings and revenue
Pediatrix Medical Group posted Q2 earnings of $0.49 per share, up from $0.46 a year earlier.
Net income edged up to $40 million, while net revenue rose 4% to $488 million versus the prior-year quarter.
